Mitomycin-C induced hemolytic uremic syndrome: a case report

Ren Fail. 2002 May;24(3):373-7. doi: 10.1081/jdi-120005372.

Abstract

Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. We report a patient with a colonic adenocarcinoma who developed hemolytic uremic syndrome after receiving 85 mg/m2 of the drug. The patient was left untreated and died 5 months after this diagnosis was made, of a second malignancy. Differential diagnosis and treatment of this condition are discussed.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy
  • Alkylating Agents / adverse effects*
  • Antibiotics, Antineoplastic / adverse effects*
  • Colonic Neoplasms / diagnosis
  • Colonic Neoplasms / drug therapy
  • Diagnosis, Differential
  • Female
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Hemolytic-Uremic Syndrome / diagnosis
  • Humans
  • Middle Aged
  • Mitomycin / adverse effects*
  • Renal Insufficiency / chemically induced
  • Renal Insufficiency / diagnosis

Substances

  • Alkylating Agents
  • Antibiotics, Antineoplastic
  • Mitomycin